We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » OIG SETTLES MONETARY PENALTY CASE VS. DEVICE SUPPLIER; LARGEST AWARD IN AGENCY HISTORY

OIG SETTLES MONETARY PENALTY CASE VS. DEVICE SUPPLIER; LARGEST AWARD IN AGENCY HISTORY

May 16, 2006

HHS' Office of Inspector General (OIG) has entered into a settlement agreement and corporate integrity agreement (CIA) with Lincare Holdings and its subsidiary Lincare, the agency has announced.

Lincare, headquartered in Clearwater, Fla., is one of the largest durable medical equipment suppliers in the U.S. The settlement resolves allegations that Lincare paid illegal kickbacks and violated the Physician Self-Referral Law, the OIG said. Under the settlement -- the largest civil monetary penalty ever collected by OIG -- the company paid $10 million and entered into a 5-year company-wide CIA.

Lincare engaged in a nationwide scheme to pay physicians illegal kickbacks to refer patients to the company, the OIG alleged. The company rewarded referring physicians with sporting and entertainment tickets, gift certificates, golf outings and equipment, fishing trips, meals, advertising expenses, and office and medical equipment, the OIG said. The kickbacks were disguised as consulting fees.

The OIG statement can be viewed at http://oig.hhs.gov/publications/docs/press/2006/Lincare051506.pdf (http://oig.hhs.gov/publications/docs/press/2006/Lincare051506.pdf).

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing